Zai Lab (shanghai) Co., Ltd.

This Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…

This early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.

This study tests a new drug called ZL-1310 in adults with advanced neuroendocrine carcinomas (a type of solid tumor) that have worsened after platinum-based chemotherapy. The trial has two parts: Phase 1b checks safety and side effects, while Phase 2 looks at whether the drug shr…

This study tests a new drug called ZL-1310, alone or with standard treatments (atezolizumab and carboplatin), in people with small cell lung cancer. About 339 participants will join to see if the combination is safe and shrinks tumors. The goal is to find better ways to control t…

This study tests a new drug called ZL-1109 for people with moderate to severe thyroid eye disease, a condition that causes eye bulging and discomfort. About 99 Chinese adults will receive either the drug or a placebo to see if it safely reduces eye bulging by at least 2 millimete…

This early-stage trial is testing a new drug called ZL-1503 for safety and how the body processes it. It involves 84 participants: first healthy volunteers, then people with moderate to severe atopic dermatitis (eczema). The study is 'double-blind' and 'placebo-controlled,' meani…